1+ day, 11+ hour ago  (524+ words) Neuro EXPLORER can image small brain regions involved in the disease Written by Andrea Lobo | June 18, 2026 UZ Leuven and KU Leuven, two institutions in Belgium, have introduced Neuro EXPLORER PET into clinical practice. The ultra-high-resolution PET scanner, developed by United…...

2+ day, 11+ hour ago  (515+ words) Combining the scan with biomarker tests uncovers critical brain changes Written by Andrea Lobo | June 17, 2026 Neuropacs" Automated Imaging Differentiation of Parkinsonism (AIDP) software accurately detected brain changes related to Parkinson"s disease across different patient groups, including some who tested…...

3+ day, 11+ hour ago  (530+ words) Goradia Foundation grant focusing on potential long-term use of ACI-7104 Written by Andrea Lobo | June 16, 2026 AC Immune has been awarded $4 million to extend the first part of an ongoing clinical trial that's testing ACI-7104, its experimental vaccine targeting alpha-synuclein protein…...

4+ day, 11+ hour ago  (442+ words) BIA 28-6156 didn't meet goals in Phase 2 trial involving gene mutation Written by Andrea Lobo | June 15, 2026 BIA 28-6156, a small-molecule therapy developed by Bial for GBA-related Parkinson's disease, did not slow disease progression in a Phase 2 clinical trial involving people with mutations…...

1+ week, 2+ day ago  (272+ words) I may have found the perfect exercise Written by Christine Scheer | June 12, 2026 About four months ago, someone sent me a social media post about a Parkinson's walking group. This group looked like a happening place; they used walking poles, had…...

1+ week, 10+ hour ago  (464+ words) Review identifies 132 areas of impact, including quality of life and fatigue Written by Andrea Lobo | June 12, 2026 A comprehensive review of the scientific literature identified more than 100 distinct ways in which off episodes affect people with Parkinson's disease, highlighting a multifaceted…...

1+ week, 1+ day ago  (366+ words) Phase 2a SLEIPNIR platform trial to assess safety, tolerability, brain penetration Written by Andrea Lobo | June 11, 2026 Foresee Pharmaceuticals" oral therapy mirivadelgat has been selected to enter the Phase 2a SLEIPNIR platform trial, which is testing several experimental treatments for Parkinson"s disease....

1+ week, 2+ day ago  (660+ words) Evidence for motor and nonmotor benefits remains limited, researchers say Written by Lila Levinson, Ph D | June 10, 2026 FMT was generally safe and beneficial for gastrointestinal symptoms in people with Parkinson's. Evidence for broader motor and nonmotor benefits is inconsistent, and…...

1+ week, 4+ day ago  (435+ words) Mouse study targets Glu N2 B receptor subunit in movement-control neurons Written by Marisa Wexler, MS | June 8, 2026 In a mouse model, dyskinesia was linked to abnormal levels of the Glu N2 B receptor subunit in specific movement-control neurons. An experimental gene therapy…...

2+ week, 1+ day ago  (374+ words) Lysoway Therapeutics is developing TMEM175 agonist to aid lysosomes Written by Andrea Lobo | June 4, 2026 The Michael J. Fox Foundation for Parkinson's Research (MJFF) awarded Lysoway Therapeutics $3. 4 million in funding to support the development of an investigational therapy targeting the TMEM175 protein. The grant…...